These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20033465)

  • 1. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
    Halperin SA; Diaz-Mitoma F; Dull P; Anemona A; Ceddia F
    Eur J Clin Microbiol Infect Dis; 2010 Mar; 29(3):259-67. PubMed ID: 20033465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
    Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
    Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
    Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
    Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
    Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
    Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
    Tregnaghi M; Lopez P; Stamboulian D; Graña G; Odrljin T; Bedell L; Dull PM
    Int J Infect Dis; 2014 Sep; 26():22-30. PubMed ID: 24980467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
    Johnston W; Essink B; Kirstein J; Forleo-Neto E; Percell S; Han L; Keshavan P; Smolenov I
    Pediatr Infect Dis J; 2016 Jan; 35(1):e19-27. PubMed ID: 26398741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
    Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
    Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
    Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.